These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Kivistö KT; Lamberg TS; Neuvonen PJ Pharmacol Toxicol; 1999 Feb; 84(2):94-7. PubMed ID: 10068153 [TBL] [Abstract][Full Text] [Related]
5. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442 [TBL] [Abstract][Full Text] [Related]
6. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Barbhaiya RH; Shukla UA; Pfeffer M; Pittman KA; Shrotriya R; Laroudie C; Gammans RE Eur J Clin Pharmacol; 1994; 46(1):41-7. PubMed ID: 7911763 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. Dockens RC; Salazar DE; Fulmor IE; Wehling M; Arnold ME; Croop R J Clin Pharmacol; 2006 Nov; 46(11):1308-12. PubMed ID: 17050795 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. Berlin I; Chalon S; Payan C; Schöllnhammer G; Cesselin F; Varoquaux O; Puech AJ Br J Clin Pharmacol; 1995 Mar; 39(3):243-9. PubMed ID: 7619663 [TBL] [Abstract][Full Text] [Related]
17. Concentrations and effects of buspirone are considerably reduced by rifampicin. Lamberg TS; Kivistö KT; Neuvonen PJ Br J Clin Pharmacol; 1998 Apr; 45(4):381-5. PubMed ID: 9578186 [TBL] [Abstract][Full Text] [Related]
18. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action. Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425 [TBL] [Abstract][Full Text] [Related]
19. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Wong H; Dockens RC; Pajor L; Yeola S; Grace JE; Stark AD; Taub RA; Yocca FD; Zaczek RC; Li YW Drug Metab Dispos; 2007 Aug; 35(8):1387-92. PubMed ID: 17494642 [TBL] [Abstract][Full Text] [Related]
20. The clinical pharmacokinetics of levofloxacin. Fish DN; Chow AT Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]